Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization12. Issue 12 (21st October 2016)
- Record Type:
- Journal Article
- Title:
- Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization12. Issue 12 (21st October 2016)
- Main Title:
- Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization12
- Authors:
- Herdman, Christine A.
Strecker, Tracy E.
Tanpure, Rajendra P.
Chen, Zhi
Winters, Alex
Gerberich, Jeni
Liu, Li
Hamel, Ernest
Mason, Ralph P.
Chaplin, David J.
Trawick, Mary Lynn
Pinney, Kevin G. - Abstract:
- Abstract : Synthesis of benzocyclooctene and indene analogues inspired by colchicine and combretastatin A-4. Abstract : The natural products colchicine and combretastatin A-4 (CA4 ) have been inspirational for the design and synthesis of structurally related analogues and spin-off compounds as inhibitors of tubulin polymerization. The discovery that a water-soluble phosphate prodrug salt ofCA4 (referred to asCA4P ) is capable of imparting profound and selective damage to tumor-associated blood vessels paved the way for the development of a new therapeutic approach for cancer treatment utilizing small-molecule inhibitors of tubulin polymerization that also act as vascular disrupting agents (VDAs). Combination of salient structural features associated with colchicine andCA4 led to the design and synthesis of a variety of fused aryl-cycloalkyl and aryl-heterocyclic compounds that function as inhibitors of tubulin polymerization. Prominent among these compounds is a benzosuberene analogue (referred to asKGP18 ), which demonstrates sub-nM cytotoxicity against human cancer cell lines and functions (when administered as a water-soluble prodrug salt) as a VDA in mouse models. Structure activity relationship considerations led to the evaluation of benzocyclooctyl [6, 8 fused] and indene [6, 5 fused] ring systems. Four benzocyclooctene and four indene analogues were prepared and evaluated biologically. Three of the benzocyclooctene analogues were active as inhibitors of tubulinAbstract : Synthesis of benzocyclooctene and indene analogues inspired by colchicine and combretastatin A-4. Abstract : The natural products colchicine and combretastatin A-4 (CA4 ) have been inspirational for the design and synthesis of structurally related analogues and spin-off compounds as inhibitors of tubulin polymerization. The discovery that a water-soluble phosphate prodrug salt ofCA4 (referred to asCA4P ) is capable of imparting profound and selective damage to tumor-associated blood vessels paved the way for the development of a new therapeutic approach for cancer treatment utilizing small-molecule inhibitors of tubulin polymerization that also act as vascular disrupting agents (VDAs). Combination of salient structural features associated with colchicine andCA4 led to the design and synthesis of a variety of fused aryl-cycloalkyl and aryl-heterocyclic compounds that function as inhibitors of tubulin polymerization. Prominent among these compounds is a benzosuberene analogue (referred to asKGP18 ), which demonstrates sub-nM cytotoxicity against human cancer cell lines and functions (when administered as a water-soluble prodrug salt) as a VDA in mouse models. Structure activity relationship considerations led to the evaluation of benzocyclooctyl [6, 8 fused] and indene [6, 5 fused] ring systems. Four benzocyclooctene and four indene analogues were prepared and evaluated biologically. Three of the benzocyclooctene analogues were active as inhibitors of tubulin polymerization (IC50 < 5 μM), and benzocyclooctene phenol23 was comparable toKGP18 in terms of potency. The analogous indene-based compound31 also functioned as an inhibitor of tubulin polymerization (IC50 = 11 μM) with reduced potency. The most potent inhibitor of tubulin polymerization from this group was benzocyclooctene analogue23, and it was converted to its water-soluble prodrug salt24 to assess its potential as a VDA. Preliminary in vivo studies, which utilized the MCF7-luc-GFP-mCherry breast tumor in a SCID mouse model, demonstrated that treatment with24 (120 mg kg −1 ) resulted in significant vascular shutdown, as evidenced by bioluminescence imaging at 4 h post administration, and that the effect continued at both 24 and 48 h. Contemporaneous studies withCA4P, a clinically relevant VDA, were carried out as a positive control. … (more)
- Is Part Of:
- MedChemComm. Volume 7:Issue 12(2016:Dec.)
- Journal:
- MedChemComm
- Issue:
- Volume 7:Issue 12(2016:Dec.)
- Issue Display:
- Volume 7, Issue 12 (2016)
- Year:
- 2016
- Volume:
- 7
- Issue:
- 12
- Issue Sort Value:
- 2016-0007-0012-0000
- Page Start:
- 2418
- Page End:
- 2427
- Publication Date:
- 2016-10-21
- Subjects:
- Pharmaceutical chemistry -- Periodicals
615.19 - Journal URLs:
- http://pubs.rsc.org/en/journals/journalissues/md ↗
http://www.rsc.org/ ↗ - DOI:
- 10.1039/c6md00459h ↗
- Languages:
- English
- ISSNs:
- 2040-2503
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5424.685000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 1358.xml